ABSTRACT
Despite advances in non-small cell lung cancer (NSCLC) research, this is still the most common cancer type that has been diagnosed up to date. microRNAs have emerged as useful clinical biomarkers in both tissue and liquid biopsy. However, there are no reliable predictive biomarkers for clinical use. We evaluated the preclinical use of seven candidate miRNAs previously identified by our group. We collected a total of 120 prospective samples from 88 NSCLC patients. miRNA levels were analyzed via qRT-PCR from tissue and blood samples. miR-124 gene target prediction was performed using RNA sequencing data from our group and interrogating data from 2952 NSCLC patients from two public databases. We found higher levels of all seven miRNAs in tissue compared to plasma samples, except for miR-124. Our findings indicate that levels of miR-124, both free-circulating and within exosomes, are increased throughout the progression of the disease, suggesting its potential as a marker of disease progression in both advanced and early stages. Our bioinformatics approach identified KPNA4 and SPOCK1 as potential miR-124 targets in NSCLC. miR-124 levels can be used to identify early-stage NSCLC patients at higher risk of relapse.
Subject(s)
Carcinoma, Non-Small-Cell Lung , Exosomes , Lung Neoplasms , MicroRNAs , Humans , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Prognosis , Prospective Studies , Biomarkers, Tumor/metabolism , Neoplasm Recurrence, Local/metabolism , MicroRNAs/metabolism , Exosomes/metabolism , Liquid Biopsy , Proteoglycans/metabolism , alpha Karyopherins/metabolismABSTRACT
Circular RNAs (circRNAs) are a class of non-coding RNAs featuring a covalently closed ring structure formed through backsplicing. circRNAs are broadly expressed and contribute to biological processes through a variety of functions. Standard gain-of-function and loss-of-function approaches to study gene functions have significant limitations when studying circRNAs. Overexpression studies in particular suffer from the lack of efficient genetic tools. While mammalian expression plasmids enable transient circRNA overexpression in cultured cells, most cell biological studies require long-term ectopic expression. Here we report the development and characterization of genetic tools enabling stable circRNA overexpression in vitro and in vivo. We demonstrated that circRNA expression constructs can be delivered to cultured cells via transposons, whereas lentiviral vectors have limited utility for the delivery of circRNA constructs due to viral RNA splicing in virus-producing cells. We further demonstrated ectopic circRNA expression in a hepatocellular carcinoma mouse model upon circRNA transposon delivery via hydrodynamic tail vein injection. Furthermore, we generated genetically engineered mice harbouring circRNA expression constructs. We demonstrated that this approach enables constitutive, global circRNA overexpression as well as inducible circRNA expression directed specifically to melanocytes in a melanoma mouse model. These tools expand the genetic toolkit available for the functional characterization of circRNAs.
Subject(s)
MicroRNAs , RNA, Circular , Animals , Mammals/genetics , Mice , MicroRNAs/genetics , RNA/genetics , RNA/metabolism , RNA Splicing , RNA, Viral/geneticsABSTRACT
Overexpression of PHGDH, the rate-limiting enzyme in the serine synthesis pathway, promotes melanomagenesis, melanoma cell proliferation, and survival of metastases in serine-low environments such as the brain. While PHGDH amplification explains PHGDH overexpression in a subset of melanomas, we find that PHGDH levels are universally increased in melanoma cells due to oncogenic BRAFV600E promoting PHGDH transcription through mTORC1-mediated translation of ATF4. Importantly, PHGDH expression was critical for melanomagenesis as depletion of PHGDH in genetic mouse models blocked melanoma formation. Despite BRAFV600E-mediated upregulation, PHGDH was further induced by exogenous serine restriction. Surprisingly, BRAFV600E inhibition diminished serine restriction-mediated PHGDH expression by preventing ATF4 induction, creating a potential vulnerability whereby melanoma cells could be specifically starved of serine by combining BRAFV600E inhibition with exogenous serine restriction. Indeed, we show that this combination promoted cell death in vitro and attenuated melanoma growth in vivo. This study identified a melanoma cell-specific PHGDH-dependent vulnerability.
ABSTRACT
Small extracellular vesicles (sEVs) in the blood of cancer patients contain higher amounts of tumor markers than those identified as free-circulating. miRNAs have significant biomedical relevance due to their high stability and feasible detection. However, there is no reliable endogenous control available to measure sEVs-miRNA content, impairing the acquisition of standardized consistent measurements in cancer liquid biopsy. In this study, we identified three miRNAs from a panel of nine potential normalizers that emerged from a comprehensive analysis comparing the sEV-miRNA profile of six lung and ovarian human cancer cell lines in the absence of or under different conditions. Their relevance as normalizers was tested in 26 additional human cancer cell lines from nine different tumor types undergoing chemotherapy or radiotherapy treatment. The validation cohorts were comprised of 242 prospective plasma and ascitic fluid samples from three different human tumor types. Variability and normalization properties were tested in comparison to miR-16, the most used control to normalize free-circulating miRNAs in plasma. Our results indicate that miR-151a is consistently represented in small extracellular vesicles with minimal variability compared to miR-16, providing a novel normalizer to measure small extracellular vesicle miRNA content that will benefit liquid biopsy in cancer patients.
ABSTRACT
Somatic copy-number alterations (CNA) promote cancer, but the underlying driver genes may not be comprehensively identified if only the functions of the encoded proteins are considered. mRNAs can act as competitive endogenous RNAs (ceRNA), which sponge miRNAs to posttranscriptionally regulate gene expression in a protein coding-independent manner. We investigated the contribution of ceRNAs to the oncogenic effects of CNAs. Chromosome 1q gains promoted melanoma progression and metastasis at least in part through overexpression of three mRNAs with ceRNA activity: CEP170, NUCKS1, and ZC3H11A. These ceRNAs enhanced melanoma metastasis by sequestering tumor suppressor miRNAs. Orthogonal genetic assays with miRNA inhibitors and target site blockers, along with rescue experiments, demonstrated that miRNA sequestration is critical for the oncogenic effects of CEP170, NUCKS1, and ZC3H11A mRNAs. Furthermore, chromosome 1q ceRNA-mediated miRNA sequestration alleviated the repression of several prometastatic target genes. This regulatory RNA network was evident in other cancer types, suggesting chromosome 1q ceRNA deregulation as a common driver of cancer progression. Taken together, this work demonstrates that ceRNAs mediate the oncogenicity of somatic CNAs. SIGNIFICANCE: The function of CEP170, NUCKS1, and ZC3H11A mRNAs as competitive endogenous RNAs that sequester tumor suppressor microRNAs underlies the oncogenic activity of chromosome 1q gains.
Subject(s)
Melanoma , MicroRNAs , RNA, Long Noncoding , Carcinogenesis/genetics , Chromosomes , Gene Expression Regulation, Neoplastic , Gene Regulatory Networks , Humans , Melanoma/genetics , MicroRNAs/genetics , RNA, Long Noncoding/genetics , RNA, Messenger/geneticsABSTRACT
Non-coding RNAs are emerging as critical molecules in the genesis, progression, and therapy resistance of cutaneous melanoma. This includes circular RNAs (circRNAs), a class of non-coding RNAs with distinct characteristics that forms through non-canonical back-splicing. In this review, we summarize the features and functions of circRNAs and introduce the current knowledge of the roles of circRNAs in melanoma. We also highlight the various mechanisms of action of the well-studied circRNA CDR1as and describe how it acts as a melanoma tumor suppressor. We further discuss the utility of circRNAs as biomarkers, therapeutic targets, and therapeutic agents in melanoma and outline challenges that must be overcome to comprehensively characterize circRNA functions.
Subject(s)
Melanoma , RNA, Circular , Skin Neoplasms , Genes, Tumor Suppressor , Humans , RNA Splicing , Melanoma, Cutaneous MalignantABSTRACT
The miR-29 family of microRNAs is encoded by two clusters, miR-29b1~a and miR-29b2~c, and is regulated by several oncogenic and tumor suppressive stimuli. While in vitro evidence suggests a tumor suppressor role for miR-29 in melanoma, the mechanisms underlying its deregulation and contribution to melanomagenesis have remained elusive. Using various in vitro systems, we show that oncogenic MAPK signaling paradoxically stimulates transcription of pri-miR-29b1~a and pri-miR-29b2~c, the latter in a p53-dependent manner. Expression analyses in melanocytes, melanoma cells, nevi, and primary melanoma revealed that pri-miR-29b2~c levels decrease during melanoma progression. Inactivation of miR-29 in vivo with a miRNA sponge in a rapid melanoma mouse model resulted in accelerated tumor development and decreased overall survival, verifying tumor suppressive potential of miR-29 in melanoma. Through integrated RNA sequencing, target prediction, and functional assays, we identified the transcription factors MAFG and MYBL2 as bona fide miR-29 targets in melanoma. Our findings suggest that attenuation of miR-29b2~c expression promotes melanoma development, at least in part, by derepressing MAFG and MYBL2.
ABSTRACT
BACKGROUND: In an effort to contribute to overcoming the platinum resistance exhibited by most solid tumors, we performed an array of epigenetic approaches, integrating next-generation methodologies and public clinical data to identify new potential epi-biomarkers in ovarian cancer, which is considered the most devastating of gynecological malignancies. METHODS: We cross-analyzed data from methylome assessments and restoration of gene expression through microarray expression in a panel of four paired cisplatin-sensitive/cisplatin-resistant ovarian cancer cell lines, along with publicly available clinical data from selected individuals representing the state of chemoresistance. We validated the methylation state and expression levels of candidate genes in each cellular phenotype through Sanger sequencing and reverse transcription polymerase chain reaction, respectively. We tested the biological role of selected targets using an ectopic expression plasmid assay in the sensitive/resistant tumor cell lines, assessing the cell viability in the transfected groups. Epigenetic features were also assessed in 189 primary samples obtained from ovarian tumors and controls. RESULTS: We identified PAX9 and FKBP1B as potential candidate genes, which exhibited epigenetic patterns of expression regulation in the experimental approach. Re-establishment of FKBP1B expression in the resistant OVCAR3 phenotype in which this gene is hypermethylated and inhibited allowed it to achieve a degree of platinum sensitivity similar to the sensitive phenotype. The evaluation of these genes at a translational level revealed that PAX9 hypermethylation leads to a poorer prognosis in terms of overall survival. We also set a precedent for establishing a common epigenetic signature in which the validation of a single candidate, MEST, proved the accuracy of our computational pipelines. CONCLUSIONS: Epigenetic regulation of PAX9 and FKBP1B genes shows that methylation in non-promoter areas has the potential to control gene expression and thus biological consequences, such as the loss of platinum sensitivity. At the translational level, PAX9 behaves as a predictor of chemotherapy response to platinum in patients with ovarian cancer. This study revealed the importance of the transcript-specific study of each gene under potential epigenetic regulation, which would favor the identification of new markers capable of predicting each patient's progression and therapeutic response.
Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Carcinoma, Ovarian Epithelial/drug therapy , DNA Methylation/drug effects , Epigenesis, Genetic/drug effects , Ovarian Neoplasms/drug therapy , PAX9 Transcription Factor/genetics , Platinum Compounds/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Cell Line, Tumor/drug effects , Cisplatin/therapeutic use , Drug Resistance, Neoplasm/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Genetic Variation , Humans , Middle Aged , SpainABSTRACT
Cancer is one of the leading causes of death worldwide and it can affect any part of the organism. It arises as a consequence of the genetic and epigenetic changes that lead to the uncontrolled growth of the cells. The epigenetic machinery can regulate gene expression without altering the DNA sequence, and it comprises methylation of the DNA, histones modifications, and non-coding RNAs. Alterations of these gene-expression regulatory elements can be produced by an imbalance of the intracellular environment, such as the one derived by oxidative stress, to promote cancer development, progression, and resistance to chemotherapeutic treatments. Here we review the current literature on the effect of oxidative stress in the epigenetic machinery, especially over the largely unknown ncRNAs and its consequences toward cancer development and progression.
ABSTRACT
The cumbersome and time-consuming process of generating new mouse strains and multiallelic experimental animals often hinders the use of genetically engineered mouse models (GEMM) in cancer research. Here, we describe the development and validation of an embryonic stem cell (ESC)-GEMM platform for rapid modeling of melanoma in mice. The platform incorporates 12 clinically relevant genotypes composed of combinations of four driver alleles (LSL-BrafV600E, LSL-NrasQ61R, PtenFlox, and Cdkn2aFlox) and regulatory alleles to spatiotemporally control the perturbation of genes of interest. The ESCs produce high-contribution chimeras, which recapitulate the melanoma phenotypes of conventionally bred mice. Using the ESC-GEMM platform to modulate Pten expression in melanocytes in vivo, we highlighted the utility and advantages of gene depletion by CRISPR-Cas9, RNAi, or conditional knockout for melanoma modeling. Moreover, complementary genetic methods demonstrated the impact of Pten restoration on the prevention and maintenance of Pten-deficient melanomas. Finally, we showed that chimera-derived melanoma cell lines retain regulatory allele competency and are a powerful resource to complement ESC-GEMM chimera experiments in vitro and in syngeneic grafts in vivo Thus, when combined with sophisticated genetic tools, the ESC-GEMM platform enables rapid, high-throughput, and versatile studies aimed at addressing outstanding questions in melanoma biology.Significance: This study presents a high-throughput and versatile ES cell-based mouse modeling platform that can be combined with state-of-the-art genetic tools to address unanswered questions in melanoma in vivo See related commentary by Thorkelsson et al., p. 655.
Subject(s)
Embryonic Stem Cells , Melanoma/genetics , Animals , Clustered Regularly Interspaced Short Palindromic Repeats , Disease Models, Animal , Melanocytes , Mice , Proto-Oncogene Proteins B-raf/geneticsABSTRACT
INTRODUCTION: MicroRNA-7 (miR-7) has a suppressive role in lung cancer and alterations in its DNA methylation may contribute to tumorigenesis. As COPD patients with emphysema have a higher risk of lung cancer than other COPD phenotypes, we compared the miR-7 methylation status among smoker subjects and patients with various COPD phenotypes to identify its main determinants. METHODS: 30 smoker subjects without airflow limitation and 136 COPD patients without evidence of cancer were recruited in a prospective study. Clinical and functional characteristics were assessed and patients were classified into: frequent exacerbator, emphysema, chronic bronchitis and asthma COPD overlap (ACO). DNA collected from buccal epithelial samples was isolated and bisulfite modified. miR-7 methylation status was evaluated by quantitative methylation-specific polymerase chain reaction (qMSP). RESULTS: miR-7 Methylated levels were higher in COPD patients than in smokers without airflow limitation (23.7±12.4 vs. 18.5±8.8%, p=0.018). Among COPD patients, those with emphysema had higher values of methylated miR-7 (27.1±10.2%) than those with exacerbator (19.4±9.9%, p=0.004), chronic bronchitis (17.3±9.0%, p=0.002) or ACO phenotypes (16.0±7.2%, p=0.010). After adjusting for clinical parameters, differences between emphysematous patients and those with other phenotypes were retained. In COPD patients, advanced age, mild-moderate airflow limitation, reduced diffusing capacity and increased functional residual capacity were identified as independent predictors of methylated miR-7 levels. CONCLUSION: The increase of miR-7 methylation levels experienced by COPD patients occurs mainly at the expense of the emphysema phenotype, which might contribute to explain the higher incidence of lung cancer in these patients.
Subject(s)
Emphysema , MicroRNAs , Pulmonary Disease, Chronic Obstructive , DNA Methylation , Humans , MicroRNAs/genetics , Prospective Studies , Pulmonary Disease, Chronic Obstructive/geneticsABSTRACT
Despite often leading to platinum resistance, platinum-based chemotherapy continues to be the standard treatment for many epithelial tumors. In this study we analyzed and validated the cytogenetic alterations that arise after treatment in four lung and ovarian paired cisplatin-sensitive/resistant cell lines by 1-million microarray-based comparative genomic hybridization (array-CGH) and qRT-PCR methodologies. RNA-sequencing, functional transfection assays, and gene-pathway activity analysis were used to identify genes with a potential role in the development of this malignancy. The results were further explored in 55 lung and ovarian primary tumors and control samples, and in two extensive in silico databases. Long-term cell exposure to platinum induces the frequent deletion of ITF2 gene. Its expression re-sensitized tumor cells to platinum and recovered the levels of Wnt/ß-catenin transcriptional activity. ITF2 expression was also frequently downregulated in epithelial tumors, predicting a worse overall survival. We also identified an inverse correlation between ITF2 and HOXD9 expression, revealing that Non-small cell lung cancer (NSCLC) patients with lower expression of HOXD9 had a better overall survival rate. We defined the implication of ITF2 as a molecular mechanism behind the development of cisplatin resistance probably through the activation of the Wnt-signaling pathway. This data highlights the possible role of ITF2 and HOXD9 as novel therapeutic targets for platinum resistant tumors.
ABSTRACT
Non-small-cell lung cancer (NSCLC) is the most common malignancy worldwide. Platinum-based chemotherapy is the standard of care for these patients. Recent research showed that miR-7 methylation status is a biomarker of cisplatin resistance in lung and ovarian cancer cells, which is one of the major limitations associated with their clinical management. The aim of the present study is to provide clinical insights associated with this novel potential biomarker in NSCLC patients by comparing the miR-7 methylation status with the cisplatin treatment response. Our results analyzed in 81 samples show that miR-7 methylation is a common event in tumor tissue and it is more frequent as the stage of the disease advances, remaining in 75% of metastatic patients. Tumor miR-7 unmethylation trend to a better PFS in early stages, and when our data was validated in an extended "in silico" cohort of 969 patients we obtained a significant increment in PFS and OS in those patients harboring miR-7 unmethylated (p = 0.010 and p = 0.007 respectively). When we select those early-stages patients harbouring miR-7 methylation, we observed that adenocarcinoma patients present a dramatic decrease in PFS compared with squamous cell carcinoma patients (median 18.9 versus 59.7 months, p = 0.002). In conclusion, our results show that presence of miR-7 methylation in early-stage NSCLC is suggestive of aggressive behavior, especially for adenocarcinoma patients. One major challenge in early diagnosis in NSCLC is identify the subgroup of patients that could benefit for adjuvant therapy, our data establish the basis for epigenetic classification on early-stage NSCLC that could influence treatment decisions in the future.
ABSTRACT
Long noncoding RNAs (lncRNAs) are critical regulators of cell biology whose alteration can lead to the development of diseases such as cancer. The potential role of lncRNAs and their epigenetic regulation in response to platinum treatment are largely unknown. We analyzed four paired cisplatin-sensitive/resistant non-small cell lung cancer and ovarian cancer cell lines. The epigenetic landscape of overlapping and cis-acting lncRNAs was determined by combining human microarray data on 30,586 lncRNAs and 20,109 protein coding mRNAs with whole-genome bisulfite sequencing. Selected candidate lncRNAs were further characterized by PCR, gene-ontology analysis, and targeted bisulfite sequencing. Differential expression in response to therapy was observed more frequently in cis-acting than in overlapping lncRNAs (78% vs. 22%, fold change ≥1.5), while significantly altered methylation profiles were more commonly associated with overlapping lncRNAs (29% vs. 8%; P value <0.001). Moreover, overlapping lncRNAs contain more CpG islands (CGIs) (25% vs. 17%) and the majority of CGI-containing overlapping lncRNAs share these CGIs with their associated coding genes (84%). The differences in expression between sensitive and resistant cell lines were replicated in 87% of the selected candidates (P<0.05), while our bioinformatics approach identifying differential methylation was confirmed in all of the selected lncRNAs (100%). Five lncRNAs under epigenetic regulation appear to be involved in cisplatin resistance (AC091814.2, AC141928.1, RP11-65J3.1-002, BX641110, and AF198444). These novel findings provide new insights into epigenetic mechanisms and acquired resistance to cisplatin that highlight specific lncRNAs, some with unknown function, that may signal strategies in epigenetic therapies.
Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Epigenesis, Genetic , Ovarian Neoplasms/drug therapy , RNA, Long Noncoding/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cisplatin/adverse effects , Cisplatin/pharmacology , Computational Biology , Drug Resistance, Neoplasm/genetics , Female , Gene Expression Regulation, Neoplastic , Gene Ontology , Humans , Microarray Analysis , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , RNA, Messenger/genetics , Whole Genome SequencingABSTRACT
One of the major limitations associated with platinum use is the resistance that almost invariably develops in different tumor types. In the current study, we sought to identify epigenetically regulated microRNAs as novel biomarkers of platinum resistance in lung and ovarian cancers, the ones with highest ratios of associated chemo-resistance. Methods: We combined transcriptomic data from microRNA and mRNA under the influence of an epigenetic reactivation treatment in a panel of four paired cisplatin -sensitive and -resistant cell lines, followed by real-time expression and epigenetic validations for accurate candidate selection in 19 human cancer cell lines. To identify specific candidate genes under miRNA regulation, we assembled "in silico" miRNAs and mRNAs sequences by using ten different algorithms followed by qRT-PCR validation. Functional assays of site-directed mutagenesis and luciferase activity, miRNAs precursor overexpression, silencing by antago-miR and cell viability were performed to confirm their specificity in gene regulation. Results were further explored in 187 primary samples obtained from ovarian tumors and controls. Results: We identified 4 candidates, miR-7, miR-132, miR-335 and miR-148a, which deregulation seems to be a common event in the development of resistance to cisplatin in both tumor types. miR-7 presented specific methylation in resistant cell lines, and was associated with poorer prognosis in ovarian cancer patients. Our experimental results strongly support the direct regulation of MAFG through miR-7 and their involvement in the development of CDDP resistance in human tumor cells. Conclusion: The basal methylation status of miR-7 before treatment may be a potential clinical epigenetic biomarker, predictor of the chemotherapy outcome to CDDP in ovarian cancer patients. To the best of our knowledge, this is the first report linking the regulation of MAFG by miRNA-7 and its role in chemotherapy response to CDDP. Furthermore, this data highlights the possible role of MAFG as a novel therapeutic target for platinum resistant tumors.
Subject(s)
Antineoplastic Agents/pharmacology , Cisplatin/pharmacology , MafG Transcription Factor/genetics , MicroRNAs/metabolism , Ovarian Neoplasms/drug therapy , Repressor Proteins/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , DNA Methylation/drug effects , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Epigenesis, Genetic , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , MafG Transcription Factor/metabolism , MicroRNAs/genetics , Middle Aged , Neoplasm Recurrence, Local/genetics , Ovarian Neoplasms/genetics , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Repressor Proteins/metabolism , Young AdultABSTRACT
The methylation status of the IGFBP-3 gene is strongly associated with cisplatin sensitivity in patients with non-small cell lung cancer (NSCLC). In this study, we found in vitro evidence that linked the presence of an unmethylated promoter with poor response to radiation. Our data also indicate that radiation might sensitize chemotherapy-resistant cells by reactivating IGFBP-3-expression through promoter demethylation, inactivating the PI3K/AKT pathway. We also explored the IGFBP-3 methylation effect on overall survival (OS) in a population of 40 NSCLC patients who received adjuvant therapy after R0 surgery. Our results indicate that patients harboring an unmethylated promoter could benefit more from a chemotherapy schedule alone than from a multimodality therapy involving radiotherapy and platinum-based treatments, increasing their OS by 2.5 y (p = .03). Our findings discard this epi-marker as a prognostic factor in a patient population without adjuvant therapy, indicating that radiotherapy does not improve survival for patients harboring an unmethylated IGFBP-3 promoter.
Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Insulin-Like Growth Factor Binding Protein 3/metabolism , Lung Neoplasms/radiotherapy , Promoter Regions, Genetic , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/surgery , Cell Line, Tumor/radiation effects , Cell Survival/genetics , Cell Survival/radiation effects , Combined Modality Therapy , DNA Methylation , Female , Humans , Insulin-Like Growth Factor Binding Protein 3/genetics , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Lung Neoplasms/surgery , Male , Middle Aged , Phosphorylation/drug effects , Prognosis , Proto-Oncogene Proteins c-akt/metabolism , Survival Analysis , Treatment OutcomeABSTRACT
INTRODUCTION: MicroRNA-7 (miR-7) has a suppressive role in lung cancer and alterations in its DNA methylation may contribute to tumorigenesis. As COPD patients with emphysema have a higher risk of lung cancer than other COPD phenotypes, we compared the miR-7 methylation status among smoker subjects and patients with various COPD phenotypes to identify its main determinants. METHODS: 30 smoker subjects without airflow limitation and 136 COPD patients without evidence of cancer were recruited in a prospective study. Clinical and functional characteristics were assessed and patients were classified into: frequent exacerbator, emphysema, chronic bronchitis and asthma COPD overlap (ACO). DNA collected from buccal epithelial samples was isolated and bisulfite modified. miR-7 methylation status was evaluated by quantitative methylation-specific polymerase chain reaction (qMSP). RESULTS: miR-7 Methylated levels were higher in COPD patients than in smokers without airflow limitation (23.7 ± 12.4 vs. 18.5 ± 8.8 %, p = 0.018). Among COPD patients, those with emphysema had higher values of methylated miR-7 (27.1 ± 10.2 %) than those with exacerbator (19.4 ± 9.9 %, p = 0.004), chronic bronchitis (17.3 ± 9.0 %, p = 0.002) or ACO phenotypes (16.0 ± 7.2 %, p = 0.010). After adjusting for clinical parameters, differences between emphysematous patients and those with other phenotypes were retained. In COPD patients, advanced age, mild-moderate airflow limitation, reduced diffusing capacity and increased functional residual capacity were identified as independent predictors of methylated miR-7 levels. CONCLUSION: The increase of miR-7 methylation levels experienced by COPD patients occurs mainly at the expense of the emphysema phenotype, which might contribute to explain the higher incidence of lung cancer in these patients
INTRODUCCIÓN: El microRNA-7 (miR-7) tiene un papel supresor en el cáncer de pulmón, y las alteraciones en la metilación de su DNA podrían contribuir a la tumorogénesis. Como los pacientes con EPOC y enfisema presentan un mayor riesgo de sufrir cáncer de pulmón frente a otros fenotipos de EPOC, comparamos la metilación de miR-7 entre los pacientes fumadores y los pacientes con varios fenotipos de EPOC para identificar sus factores determinantes principales. MÉTODOS: Se reclutaron para un estudio prospectivo 30 sujetos fumadores sin restricciones en el flujo aéreo y 136 pacientes con EPOC sin evidencia de cáncer. Se valoraron las características clínicas y funcionales y se clasificaron a los pacientes en: exacerbaciones frecuentes, enfisema, bronquitis crónica y solapamiento de asma y EPOC (ACO, por sus siglas en inglés). Se recogió ADN a partir de muestras de epitelio bucal, se aisló y se modificó con bisulfito. El estado de metilación del miR-7 se evaluó mediante la reacción cuantitativa en cadena de la polimerasa específica de la metilación (qMPS por sus siglas en inglés). RESULTADOS: Los niveles de metilación del miR-7 fueron más altos en los pacientes con EPOC que en los fumadores sin restricciones en el flujo aéreo (23,7 ± 12,4 frente a 18,5 ± 8,8%, p = 0,018). Entre los pacientes con EPOC, aquellos con enfisema presentaban valores más altos de miR-7 metilado (27,1 ± 10,2%) que aquellos con exacerbaciones (19,4 ± 9,9%, p = 0,004), bronquitis crónica (17,3 ± 9,0%, p = 0,002) o los fenotipos ACO (16,0 ± 7,2%, p = 0,010). Tras ajustar los resultados a los parámetros clínicos, las diferencias entre los pacientes enfisematosos y aquellos con otros fenotipos permanecieron. En los pacientes con EPOC, se identificaron como predictores independientes de los niveles de metilación del miR-7 a: la edad avanzada, limitación al flujo aéreo leve-moderada, capacidad de difusión reducida y capacidad residual funcional aumentada. CONCLUSIÓN: El aumento de los niveles de metilación del miR-7 que experimentan los pacientes con EPOC ocurre principalmente a expensas del fenotipo con enfisema, lo que podría contribuir a explicar la mayor incidencia de cáncer de pulmón en estos pacientes
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Methylation , MicroRNAs/metabolism , Pulmonary Emphysema/metabolism , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/metabolism , Prospective Studies , PhenotypeABSTRACT
En el contexto de la medicina personalizada, la epigenética cobra importancia como base de prevención, diagnóstico, prognosis y tratamiento de enfermedades como el cáncer. De los distintos procesos de control epigenético, el silenciamiento génico por metilación del ADN es el más frecuente en esta patología y aporta aplicaciones clínicas muy variadas como predicción de respuesta terapéutica, prognosis asociada a las características moleculares del tumor y el seguimiento de pacientes tras la intervención quirúrgica o el tratamiento con quimioterapia. Una de las principales ventajas clínicas de estas alteraciones epigenéticas es que pueden revertirse mediante tratamientos farmacológicos, aunque se asocien con múltiples efectos secundarios. Es por ello de gran importancia continuar con el estudio de la regulación epigenética en cáncer, complementado con la biología de sistemas, lo que aportaría conocimiento sobre la implicación biológica real de estos biomarcadores, y la identificación de fármacos específicos que disminuyan estos efectos adversos y nos acerquen a la realidad de una medicina personalizada (AU)
In the context of personalised medicine, epigenetics has an important role as regards he prevention, diagnosis, prognosis, and treatment of diseases such as cancer. Of the different epigenetic control processes, gene silencing by DNA methylation is most frequent in this disease, and contributes to a wide variety of clinical applications such as, prediction of the therapeutic response, the prognosis associated with the molecular characteristics of the tumour, and the follow-up pf patients after treatment by surgery or chemotherapy. One of the main advantages of these epigenetic alterations is that they can be reversed with pharmacological treatments, although they are associated with multiple side effects. It for this reason, it is of great importance to continue studying epigenetic regulation in cancer, complementing with biological systems, as well as the identification of specific drugs that may decrease these adverse effects, and which should help to determine the real biological implications of these biomarkers and may lead to achieving personalised medicine (AU)
Subject(s)
Humans , Epigenesis, Genetic , Biomarkers, Tumor/analysis , Neoplasms/genetics , DNA Methylation/genetics , Genes, Tumor Suppressor , Histones/genetics , RNA, Messenger/geneticsABSTRACT
Objetivo: informar las manifestaciones clínicas y serológicas de pacientes con enfermedad por adyuvantes (EAH). Métodos: se analizaron los datos clínicos y serológicos de pacientes con enfermedad por adyuvantes que fueron atendidos de enero de 1993 a diciembre de 1996 en el departamento de Medicina Interna del Hospital de Especialidades del Centro Médico Nacional La Raza. Se investigaron las sustancias aplicadas, las manifestaciones clínicas, las alteraciones de laboratorio detectadas, la evolución de los pacientes y el tratamiento recibido. Resultados: se estudió a 30 mujeres con edad promedio de 35 ñ 12 años. En todos los casos existió el antecedente de aplicación de diversos aceites no identificados. Fueron 15 los pacientes que presentaron manifestaciones inespecíficas de enfermedad del tejido conjuntivo. El resto cumplieron con criterios de padecimientos definidos: lupus eritematoso sistémico (5), artritis reumatoide (4), síndrome de sobreposición (2), hepatitis autoinmune (1), tiroiditis autoinmune (1) y colitis ulcerosa crónica inespecífica (1). Se trataron con analg,sicos antiinflamatorios no esteroides, esteroides y en algunos casos antifibróticos e inmunosupresores. Cuando fue posible se extrajo quirúrgicamente el tejido fibronecrótico. La mayoría de los pacientes mejoró con el tratamiento; sin embargo, ninguna se curó y sucedieron tres fallecimientos. Conclusión: la enfermedad por adyuvantes es un padecimiento de alta morbilidad, con respuesta terap,utica parcial y es capaz de provocar la muerte. La enfermedad por adyuvantes debe tenerse presente en pacientes con manifestaciones de enfermedad autoinmune y con el antecedente de aplicación de sustancias oleosas.
Subject(s)
Humans , Female , Adult , Middle Aged , Chemotherapy, Adjuvant , Connective Tissue , Ointment Bases , Surgery, Plastic/adverse effectsABSTRACT
El texto presenta una serie de preguntas y reflexiones en torno al concepto del "otro", aquel al que miramos como diferente o como peligroso y que muchas veces es el joven calificado de pandillero, o simplemente adolescente, cuya vida en riesgo lo hace distinto para la sociedad, pidiendo "programas especiales" o un trato diferente al verlo como la causa del problema social